IN2014DN10449A - - Google Patents

Info

Publication number
IN2014DN10449A
IN2014DN10449A IN10449DEN2014A IN2014DN10449A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A IN 10449DEN2014 A IN10449DEN2014 A IN 10449DEN2014A IN 2014DN10449 A IN2014DN10449 A IN 2014DN10449A
Authority
IN
India
Prior art keywords
medicaments
medicament
substituents
salt
compound
Prior art date
Application number
Inventor
Yves Auberson
Mark Gary Bock
Dario Braga
Marco Curzi
Stephanie Kay Dodd
Stefano Luca Giaffreda
Haiyang Jiang
Piotr Karpinski
Thomas J Troxler
Tielin Wang
Xiaoyang Wang
Xuechun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN10449A publication Critical patent/IN2014DN10449A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The invention relates to compound of the formula (I) or a salt thereof wherein the substituents are as defined in the specification; to its preparation to its use as medicament and to medicaments comprising it.
IN10449DEN2014 2012-07-20 2013-07-18 IN2014DN10449A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28
PCT/IB2013/055916 WO2014013469A1 (en) 2012-07-20 2013-07-18 Carbamate/urea derivatives

Publications (1)

Publication Number Publication Date
IN2014DN10449A true IN2014DN10449A (en) 2015-08-21

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10449DEN2014 IN2014DN10449A (en) 2012-07-20 2013-07-18

Country Status (42)

Country Link
US (4) US9034874B2 (en)
EP (1) EP2875016B1 (en)
JP (1) JP6203841B2 (en)
KR (1) KR102150739B1 (en)
CN (1) CN104470911B (en)
AP (1) AP3710A (en)
AR (1) AR092354A1 (en)
AU (1) AU2013291617B2 (en)
BR (1) BR112015001207B1 (en)
CA (1) CA2878006C (en)
CL (1) CL2015000056A1 (en)
CO (1) CO7170173A2 (en)
CR (1) CR20150019A (en)
CU (1) CU24248B1 (en)
CY (1) CY1119492T1 (en)
DK (1) DK2875016T3 (en)
EA (1) EA026091B1 (en)
ES (1) ES2648512T3 (en)
GT (1) GT201500012A (en)
HK (1) HK1204609A1 (en)
HR (1) HRP20171692T1 (en)
HU (1) HUE035592T2 (en)
IL (1) IL236656A (en)
IN (1) IN2014DN10449A (en)
JO (1) JO3439B1 (en)
LT (1) LT2875016T (en)
MX (1) MX362059B (en)
MY (1) MY168752A (en)
NO (1) NO2875016T3 (en)
NZ (1) NZ702346A (en)
PE (1) PE20151155A1 (en)
PH (1) PH12014502743B1 (en)
PL (1) PL2875016T3 (en)
PT (1) PT2875016T (en)
RS (1) RS56479B1 (en)
SG (2) SG10201700188PA (en)
SI (1) SI2875016T1 (en)
TN (1) TN2014000497A1 (en)
TW (1) TWI597276B (en)
UY (1) UY34921A (en)
WO (1) WO2014013469A1 (en)
ZA (1) ZA201408805B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088256A1 (en) 2011-10-08 2014-05-21 Novartis Ag CARBAMATE / UREA DERIVATIVES AS H3 RECEIVER ANTAGONISTS
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) * 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
JP2022504364A (en) 2018-10-11 2022-01-13 ノバルティス アーゲー Use of H3R inverse agonists for the treatment of excessive daytime sleepiness associated with Parkinson's disease (PD)
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (en) 1984-07-11 1987-11-13 Sanofi Sa NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME
TW301607B (en) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
WO2001053288A1 (en) * 2000-01-20 2001-07-26 Eisai Co., Ltd. Novel piperidine compounds and drugs containing the same
CN1298715C (en) 2001-03-13 2007-02-07 先灵公司 Non-imidazole compounds as histamine H3 antagonists
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DK1615909T3 (en) 2003-04-23 2008-11-17 Glaxo Group Ltd Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders
CN1918128B (en) 2004-02-13 2011-01-26 万有制药株式会社 Fused ring 4-oxopyrimidine derivative
SE0401971D0 (en) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
KR100953878B1 (en) 2004-09-02 2010-04-22 테바 파마슈티컬 인더스트리즈 리미티드 Purification of olmesartan medoxomil
CN1976926A (en) 2004-09-02 2007-06-06 特瓦制药工业有限公司 Preparation of olmesartan medoxomil
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
JP2009514846A (en) 2005-11-04 2009-04-09 ファイザー・リミテッド Tetrahydronaphthyridine derivatives
WO2007063934A1 (en) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
US8093248B2 (en) * 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
TWI498115B (en) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd Imidazole carbonyl compounds
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
ES2601007T3 (en) 2010-01-22 2017-02-13 Taiho Pharmaceutical Co., Ltd. Piperazine compound that has a PGDS inhibitory effect
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
AR088256A1 (en) * 2011-10-08 2014-05-21 Novartis Ag CARBAMATE / UREA DERIVATIVES AS H3 RECEIVER ANTAGONISTS
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
KR102150739B1 (en) 2020-09-02
EA026091B1 (en) 2017-02-28
HUE035592T2 (en) 2018-05-28
US20150218127A1 (en) 2015-08-06
IL236656A0 (en) 2015-02-26
CN104470911B (en) 2018-04-06
US20170275264A1 (en) 2017-09-28
JP6203841B2 (en) 2017-09-27
EP2875016B1 (en) 2017-08-23
SI2875016T1 (en) 2017-11-30
PH12014502743A1 (en) 2015-02-02
AU2013291617A1 (en) 2015-01-15
SG10201700188PA (en) 2017-02-27
BR112015001207A8 (en) 2018-01-16
LT2875016T (en) 2017-11-10
MX2015000903A (en) 2015-04-10
JP2015522606A (en) 2015-08-06
CY1119492T1 (en) 2018-03-07
US9273026B2 (en) 2016-03-01
CU24248B1 (en) 2017-02-02
HRP20171692T1 (en) 2017-12-15
PL2875016T3 (en) 2018-01-31
HK1204609A1 (en) 2015-11-27
ZA201408805B (en) 2016-08-31
IL236656A (en) 2017-12-31
CA2878006A1 (en) 2014-01-23
EP2875016A1 (en) 2015-05-27
UY34921A (en) 2014-02-28
WO2014013469A1 (en) 2014-01-23
MY168752A (en) 2018-11-30
PE20151155A1 (en) 2015-08-05
GT201500012A (en) 2017-11-09
TWI597276B (en) 2017-09-01
US20140163036A1 (en) 2014-06-12
CN104470911A (en) 2015-03-25
JO3439B1 (en) 2019-10-20
CL2015000056A1 (en) 2015-03-20
NZ702346A (en) 2017-06-30
CO7170173A2 (en) 2015-01-28
US20160244426A1 (en) 2016-08-25
MX362059B (en) 2019-01-07
SG11201408020RA (en) 2015-03-30
AU2013291617B2 (en) 2015-10-01
PH12014502743B1 (en) 2015-02-02
US9034874B2 (en) 2015-05-19
DK2875016T3 (en) 2017-11-27
NO2875016T3 (en) 2018-01-20
AP2014008109A0 (en) 2014-12-31
EA201590250A1 (en) 2015-05-29
US9624192B2 (en) 2017-04-18
RS56479B1 (en) 2018-01-31
CU20150006A7 (en) 2016-02-29
CR20150019A (en) 2015-05-04
TN2014000497A1 (en) 2016-03-30
KR20150036081A (en) 2015-04-07
AR092354A1 (en) 2015-04-15
ES2648512T3 (en) 2018-01-03
PT2875016T (en) 2017-11-30
TW201408656A (en) 2014-03-01
BR112015001207B1 (en) 2022-08-09
CA2878006C (en) 2020-10-27
BR112015001207A2 (en) 2017-08-01
AP3710A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
IN2015DN03998A (en)
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
NZ608116A (en) Triazine-oxadiazoles
IN2014DN10449A (en)
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
PH12015501083A1 (en) Novel pyridine derivatives
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX343706B (en) Novel heterocyclic derivatives.
PH12015501843A1 (en) Novel pyrazol derivatives
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2015DN01119A (en)
IN2014DN01629A (en)
PH12018501709A1 (en) Naphthridinedione derivatives
MY174000A (en) Novel pyridine derivatives
MX2016004934A (en) Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX362879B (en) Novel uses.
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
IN2014DN10669A (en)
MX2015016766A (en) Novel tetrazolone derivatives.
MX365192B (en) Bendamustine derivatives and related compounds, and medical use thereof cancer therapy.
PH12015500373B1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
MX2014009084A (en) Pyrimidooxazocine derivatives as mtor - inhibitors.
TN2013000089A1 (en) Triazine-oxadiazoles
MA37778A1 (en) Carbamate / urea derivatives